Merlin Nexus

North America, New York, United States, New York

Description

Merlin Nexus, based in New York, is a company focused on crossover private equity investing in the life sciences industry.

Investor Profile

Merlin Nexus has made 7 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

Post Ipo Equity (57%)
Series A (29%)
Series E (14%)

Country Focus

United States (57%)
Canada (29%)
United Kingdom (14%)

Industry Focus

Biotechnology
Therapeutics
Health Care
Pharmaceutical
Biopharma
Medical
Oncology
Genetics
Life Science

FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Merlin Nexus frequently co-invest with?

venBio Partners

North America, California, United States, San Francisco

Co-Investments: 2

Ridgeback Capital

North America, New York, United States, New York

Co-Investments: 2

OpusPoint Partners

North America, New York, United States, New York

Co-Investments: 1

Nextech Invest

Europe, Zurich, Switzerland, Zürich

Co-Investments: 1

Bay City Capital

North America, California, United States, San Francisco

Co-Investments: 1

New Enterprise Associates

North America, California, United States, Menlo Park

Co-Investments: 2

Vision Capital Advisors

North America, New York, United States, New York

Co-Investments: 1

Alta Partners

North America, Mississippi, United States, Jackson

Co-Investments: 1

Venrock

North America, California, United States, Palo Alto

Co-Investments: 1

Caxton Advantage Life Sciences Fund

North America, New York, United States, New York

Co-Investments: 1

Which angels does Merlin Nexus often collaborate with?

Robert Simon

North America, California, United States, San Francisco

Shared Deals: 1

What are some of recent deals done by Merlin Nexus?

Zymeworks

Vancouver, British Columbia, Canada

Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics.

BiotechnologyMedicalTherapeutics

Series AJan 8, 2016

Amount Raised: $61,500,000

Adaptimmune

Oxton, York, United Kingdom

Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases.

BiopharmaBiotechnologyHealth CareMedical

Series ASep 25, 2014

Amount Raised: $104,000,000

Stem Cell Therapeutics

Toronto, Ontario, Canada

Stem Cell Therapeutics is a biopharmaceutical development company engaged in cancer stem cell discoveries to be used for cancer therapies.

BiopharmaBiotechnologyTherapeutics

Post Ipo EquityDec 16, 2013

Amount Raised: $33,000,000

WaferGen Biosystems

Fremont, California, United States

WaferGen Biosystems is a life science company offering genomic tools for targeted resequencing, genotyping and expression analysis.

BiotechnologyGeneticsLife SciencePharmaceutical

Post Ipo EquityMay 31, 2011

Amount Raised: $30,000,000

Sunesis Pharmaceuticals

South San Francisco, California, United States

Sunesis Pharmaceuticals is focused on the R&D of oncology therapeutics for the treatment of solid and hematologic cancers.

BiotechnologyHealth CareOncologyPharmaceutical

Post Ipo EquityApr 7, 2009

Amount Raised: $43,500,000

Micromet

Rockville, Maryland, United States

Micromet is a biotechnology company focused on the research, development and commercialization of novel biological products.

BiotechnologyPharmaceuticalTherapeutics

Post Ipo EquityOct 3, 2008

Amount Raised: $40,000,000

Xencor

Monrovia, California, United States

Xencor develops superior monoclonal antibody therapeutics to treat autoimmune disorders, asthma, allergic diseases and cancer.

BiotechnologyHealth CareTherapeutics

Series EOct 25, 2007

Amount Raised: $15,000,000

Merlin Nexus

Description

Investor Profile

Stage Focus

Country Focus

Industry Focus

Frequently Asked Questions

Who does Merlin Nexus frequently co-invest with?

Which angels does Merlin Nexus often collaborate with?

What are some of recent deals done by Merlin Nexus?

Ready to Raise Capital?

Pages

Free tools